An "ON'', Switch Mechanism Modulating Expression of IL-l8 and Osr2 to Enhance the Effcacy of CAR-T Therapy in Pancreatic Ductal Adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, and its fibrotic, immunosuppressive tumor microenvironment are major obstacles to chimeric antigen receptor (CAR)-T cell therapy due to the T cell exhaustion and reduction in T cell activation. This proposal asks whether inducible interleukin-18 (IL-18) and biomechanical checkpoint Osr2 knockdown can improve the efficacy of mesothelin-targeted CAR-T cells in PDAC. The proposed CAR-T cell combined split CAR as a "ON" switch which can be integrated by lenalidomide, and inserted with inducible IL-18 cassette and Osr2 shRNA cassette. The drug-dependent CAR provides a method to control the T cell expression which can help reduce the toxicity. Furthermore, IL-18 is intended to support immune activation, while Osr2 shRNA is aimed to knockdown Osr2, in turn, reduce the exhaustion of CAR-T cells associated with the tumor environment. We proposed experiments in different treatments of CAR-T cells including combining a CAR-T cell control group without any modification, CAR-T cell with both modifications, CAR-T cell with only single modification lacking either cassettes, a T-cell group, a mesothelin-negative group, and a vehicle group. By comparing the tumor burden, survival, CAR-T infiltration, exhaustion markers, and toxicity, the results will prove whether "ON" switched CAR-T cells with inducible IL-18 and Osr2 shRNA cassettes can improve the tumor control.
Authors
- 子涵 周
- Yuhan Xu
- Wanqi Luo
- Henry Liu
Institutions
- United World College of South East Asia (SG)
- Mater Dei High School (US)
Publication Details
- Journal
- Theoretical and Natural Science
- Published
- 2026-11-17
- DOI
- https://doi.org/10.54254/2753-8818/2026.39183
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Yuhan